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Abstract
Xeroderma pigmentosum is characterized by cutaneous, ophthalmological, and
neurological features. Although it is typical of childhood, late presentations can
mimic different neurodegenerative conditions. We report two families present-
ing as Huntington’s disease-like syndromes. The first case (group G) presented
with neuropsychiatric features, cognitive decline and chorea. Typical lentigines
were only noticed after the neurological disease started. The second case (group
B) presented adult-onset chorea and neuropsychiatric symptoms after an
aggressive ocular melanoma. Xeroderma pigmentosum can manifest as a Hunt-
ington’s Disease-like syndrome. Classic dermatological and oncological features
have to be investigated in choreic patients with negative genetic tests for Hunt-
ington’s disease-like phenotypes.
Introduction
Xeroderma pigmentosum (XP) is a rare autosomal recessive
disorder, caused by mutations in the nucleotide excision repair
(NER) pathway genes.1–5 This system repairs the DNA
structure after distortion caused by ultraviolet-induced photo-
products.3 Depending on the affected gene, groups from
XP-A to XP-G and XP-V have been described.5
Most XP patients present with cutaneous, ocular, and
neurological features.4–8 Some groups9 exhibit extreme
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sun sensitivity since infancy, resulting in severe sunburn
to minimal sun exposure.4 Lentigines in sun-exposed
areas and multiple cutaneous tumors are also distinctive
for the disease. Secondly, ocular surface pathology, eyelid
damage, and ophthalmic neoplasms are also common.
Neurological manifestations occur in 20–30% of cases,4
usually after the cutaneous signs. Cognitive impairment,
cerebellar signs, sensorineural hearing loss, and sensori-
motor axonal neuropathy have been reported.6,9 In
advanced cases, movement disorders may appear.7,8,10
There is noteworthy phenotypic variability among the
different XP groups and within each group.5,7 Thus, XP
can be misdiagnosed in the absence of early dermatologi-
cal features, especially in late-onset neurodegenerative
phenotypes. To our knowledge, we describe here the first
XP-G and XP-B families whose main neurological features
tightly resemble a Huntington’s disease-like (HD-like)
phenotype.
Patients and Methods
Informed consent was obtained from both patients. This
study was performed in accordance with protocols
approved by the Research Ethics Committee of Guy’s and
St Thomas’ Foundation Trust (12/LO/0325). The diagnos-
tic techniques have been previously described.5,11 Pedi-
grees were designed using the CeGaT Pedigree
Chart Designer tool.
Results
Case 1
The first case was a 63-year-old lady who had suffered
from sun sensitivity since childhood, with two episodes of
severe sunburn. She had not received any prior neuropsy-
chiatric treatments, including dopamine blocking or
Figure 1. A: case 1 pedigree (member order, age, phenotype/comments). The subjects with a dot are carriers for the mutation. B: case 2
pedigree (member order, age, phenotype/comments). The pedigree was altered to preserve anonymity.
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depleting agents. First neurological symptoms appeared
when she was 53, as mild short-term memory impair-
ment, and loss of her standards of personal hygiene. Two
years later, she complained of hearing loss and some
hyperkinetic movements were noted. During the ensuing
5 years, she experienced progressive deterioration in neu-
ropsychiatric symptoms with disinhibition, apathy and
neglect of personal hygiene; as well as worsening of bal-
ance and involuntary movements, resulting in multiple
falls. Subsequently, she was referred to a movement disor-
der specialist, who found she had generalized chorea and
commenced a treatment with 7.5 mg olanzapine, with
improvement of the hyperkinetic movements.
When assessed in our clinic, she was found to have
extensive lentigines and hypopigmented macules at sun-
exposed sites. She had photophobia, lagophthalmos, mild
keratopathy and sunken eyes. Neurologically, she was dis-
oriented and had poor executive function. She had a full
range of external ocular movements, with nystagmus, slow
initiation of saccades, and sluggish pupils. She showed
pyramidal features in the lower limbs (weakness, hyper-
reflexia and Babinski’s sign) and cerebellar signs in the
upper limbs (dysmetria and intentional tremor). The gait
was broad-based with mild camptocormia and preserved
arm swing. There was chorea in the fingers, as well as, neck
and trunk dystonia. Her clinical status progressively
declined with hallucinations, delusions, disrupted behavior
and loss of independent gait (Video S1). She died at the
age of 69, following a pulmonary thromboembolism.
Her parents came from the same village in Cyprus. The
patient was the third of seven siblings. Two siblings pre-
sented sun sensitivity, lentigines, and developed cognitive
impairment and slurred speech in their 50s. They died at
the age of 62 and 59. The fourth sibling was a lady who
showed pigmentary changes and lentigines, as well as
slurred speech and cerebellar ataxia from her 50s. Later,
she developed chorea and dementia. All the three affected
siblings developed hearing impairment. The other siblings
and the patient’s daughters were unaffected (Fig. 1A).
Her brain MRI (Fig. 2) showed nonspecific atrophy of
the brain and cerebellum without involvement of the cau-
date nuclei. Nerve conduction studies were normal. Pure
tone audiometry revealed bilateral sensorineural hearing
loss. Three blood films for acanthocytes were negative, as
well as lupus anticoagulant and anticardiolipin antibodies.
An extensive battery of genetic tests yielded negative
results, including: HD; familial prion disease (PRNP);
HDL-2 (junctophilin-3); C9orf72 expansion; denta-
torubral-pallidoluysian atrophy (DRPLA, atrophin-1);
spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7, 12, and 17.
Owing to the significant cutaneous involvement, the suspi-
cion of XP was raised and an unscheduled DNA synthesis
assay was performed. Her skin fibroblasts were defective
for the NER system, showing less than 15% of repair activ-
ity after ultraviolet radiation. XP genes sequencing showed
a homozygous single nucleotide substitution (c.869T>A) in
exon 7 of the XP-G/ERCC5 gene. This is predicted to cause
a single amino acid substitution (p.Ile290Asn) and has
been previously reported as a pathogenic missense muta-
tion.5 The patient was therefore diagnosed with late-onset
XP-G. Her affected sister was homozygous for the same
mutation. Two of the unaffected siblings were carriers.
Case 2
The second case was a 52-year-old patient who was easily
sunburned since childhood, and had lentigines since the
age of 2 years. Regarding previous pharmacological treat-
ments, no prior dopamine antagonists were noted. A mel-
anoma in the right corneal limbus was detected at the age
of 22 and the first of multiple nonmelanoma cancers was
diagnosed 7 years later. Due to a recurrence of the mela-
noma, an enucleation of the eye was performed at the age
of 36 years old. Neurologically, the patient presented at
the age of 17 with severe bilateral sensorineural hearing
loss. On examination, the patient had dense lentigines
and hypopigmented macules on sun-exposed sites such as
the face, neck and arms. There were also numerous cherry
angiomata at those sites. Choreic movements, with gri-
maces and emotional lability were noted. Despite normal
tone and power throughout, pyramidal signs were found
(brisk reflexes and bilateral Babinski’s sign). The upper
limbs showed dysmetria and intentional tremor. There
Figure 2. T2-weighted image MRI from case 1.
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was also some numbness in the right foot and a broad-
based gait. One year later, the patient complained of neck
pain spreading to the left arm. After several investigations,
she was diagnosed with a left upper lobe lung neoplasm.
The patient died at the age of 55, due to complications of
metastatic lung cancer.
One of the patient’s siblings also had multiple skin
tumors, early deafness and required enucleation of one
eye due to melanoma (Fig. 1B).
The patient’s MRI showed diffuse cerebral and cerebellar
atrophy. Genetic analysis revealed heterozygous mutations
in the XP-B/ERCC3 gene (namely, c.296T>C, resulting in
the missense mutation p.Phe99Ser; and c.1273C>T, pro-
ducing the nonsense mutation p.Arg425X), both of which
have been previously reported.5,11 Therefore, the diagnosis
of XP-B was made at the age of 43. The affected sibling
shared the same genotype.
Discussion
Both index cases exemplify the challenge of XP diagnosis
in late-onset neurodegenerative phenotypes, especially in
the presence of inconspicuous skin manifestations.
Neurological symptoms in XP patients can constitute a
major source of disability and can carry higher rates of
mortality in patients, compared to those without neuro-
logical involvement (37% vs. 29%).12 While strict photo-
protection can prevent cutaneous and ophthalmological
complications, there are no treatments to slow down the
progression of the neurological disease. Neurologists
should proactively investigate the presence of lentigines in
sun-exposed areas (face, neck, hands. . .), a previous his-
tory of easy or severe sunburn, or previous skin cancers,
even if the first cutaneous signs occurred in childhood.
Both cases fulfilled the criteria for HD-like syn-
dromes13: presence of movement disorders consistent
with HD, a negative genetic test for HD, the occurrence
of cognitive impairment and/or behavioral disturbances,
and a positive family history for analogous neurological
disorders. HD-like syndromes are challenging entities,
since a definite genetic diagnosis is reached in less than
3% of cases.14 Previously, the principal identified diseases
were C9orf72 expansion, SCA 17, HDL-1 (mutations in
PRNP) and HDL-2 (mutations in junctophilin-3). Condi-
tions such as DRPLA, neuroferritinopathy or chorea-
acanthocytosis can also present as HD-like disorders. The
main characteristics of these conditions are summarized
in Table 1.11,13–20
We have presented here the occurrence of chorea and
cognitive impairment in patients with mutations in differ-
ent genes of the NER pathway (ERCC5 and ERCC3). In a
recent report by Carre et al.,15 two XP-F patients (with
mutations in the ERCC4 gene) with chorea and cerebellar
ataxia were also described. Consequently, we reinforce the
notion that XP should be included in the differential
diagnosis of HD-like syndromes. The suspicion of XP
should be raised if there is a history of skin disorder, even
as mild as in the first presented case, and alternative
genetic testing is negative.
The cases in this report illustrate novel pathophysio-
logical mechanisms. Since a DNA repair disorder can
mimic HD, the NER pathway might be of importance
for both conditions. Apart from its role against photo-
products, the NER system also repairs the damage
caused by inner sources, such as oxidative damage.3
Due to the NER system impairment, both nuclear and
mitochondrial DNA (mtDNA) can accumulate muta-
tions. It is known that mtDNA damage and mitochon-
drial dysfunction occur in HD.2 Therefore, NER
disruption might contribute to the mitochondrial dam-
age and neuronal loss in HD. Moreover, XP-B and XP-
G are components of the transcription factor IIH
(TFIIH),21,22 which participates in transcription pro-
cesses. Dysregulation of this mechanism might con-
tribute to the neurodegeneration in XP.
Our cases emphasize the occurrence of hyperkinetic
abnormal movements in DNA repair disorders. Subtle
dystonia or tremor is often apparent in XP patients, even
in those cases without overt neurological manifestations
(PG observation). Recent reports have illustrated the rela-
tion between cerebellar atrophy and different movement
disorders in mitochondrial conditions23 and HD.24 It is
unclear whether the NER pathway could be particularly
relevant for basal ganglia metabolism or whether the
hyperkinetic movement disorders are a consequence of
the cerebellar dysfunction: further studies are needed to
elucidate the underlying pathogenesis.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Video S1. Segment 1. Dystonic posture of the neck (with
predominant laterocaput to the left and elevation of right
shoulder) and the trunk was observed. The patient
showed frequent blinking and choreic movements in the
oromandibular area and the four limbs. In addition,
lentigines in the face, the neck and hands are visible. Seg-
ment 2. The patient needed constant bilateral support of
an accompanying person due to her imbalance. It is
remarkable the broad-based gait, with small steps and dif-
ficulty in turning, as well as the stoop position.
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